L-DEP and PD-1 antibody
Phase 3Small molecule
L-DEP and PD-1 antibody is one of 6 small molecule programs targeting PD-1antibody. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Pd-1antibody
#DrugCompanyPhaseTrials
1Kuvan
BioMarin PharmaceuticalPhase 2
Libtayo
RegeneronPhase 2
Opzelura
DDizal Pharmaceuticals
Phase 2
PD-1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 2
Chidamide
CChipscreen Biosciences, Ltd.
Phase 2
L-DEP and PD-1 antibody
BBeijing Friendship Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
PD-1antibody2 trials
L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH
Not yet recruiting·—·Phase 3·NCT05315336·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for L-DEP and PD-1 antibody. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBeijing Friendship Hospital